Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma

Highlights • Canine indolent B-cell lymphoma of advanced clinical stage is an incurable disease. • Autologous heat shock proteins induced immunity against DLBCL in a canine trial. • Chemo-immunotherapy improved time to progression in dogs with indolent lymphoma. • Dogs mounting an immune response li...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2015-09, Vol.33 (39), p.5080-5086
Main Authors: Marconato, L, Stefanello, D, Sabattini, S, Comazzi, S, Riondato, F, Laganga, P, Frayssinet, P, Pizzoni, S, Rouquet, N, Aresu, L
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Cancer
Cancer therapies
Cancer Vaccines - administration & dosage
Cancer Vaccines - adverse effects
Chemotherapy
Clinical trials
Dog
Dogs
Drug Therapy - methods
Drug Therapy, Combination - methods
Female
Heat shock proteins
Histology
Hydroxyapatite
Immune response
Immunotherapy
Immunotherapy - adverse effects
Immunotherapy - methods
Indolent lymphoma
Injections, Intradermal
Lymph nodes
Lymphoma
Lymphoma, B-Cell - mortality
Lymphoma, B-Cell - therapy
Lymphoma, B-Cell - veterinary
Male
Medical prognosis
Multivariate analysis
Prospective Studies
Survival Analysis
Therapeutic Uses
Time Factors
Treatment Outcome
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Canine indolent B-cell lymphoma of advanced clinical stage is an incurable disease. • Autologous heat shock proteins induced immunity against DLBCL in a canine trial. • Chemo-immunotherapy improved time to progression in dogs with indolent lymphoma. • Dogs mounting an immune response lived significantly longer. • There were no vaccine-related side effects.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2015.08.017